Context Therapeutics and Menarini collaborate for Phase 1b/2 trial of ONA-XR + elacestrant in ER+/PR+ HER2- mBC

Context Therapeutics Inc.

Phase 1b/2 ELONA trial evaluating ONA-XR plus elacestrant expected to start Q4 2022.
Menarini supplies elacestrant at no cost; Context sponsors and funds the study.
Elacestrant Phase 3 showed 30% reduction in risk of progression or death vs SOC in ER+/HER2- mBC.
12-month PFS rate: 22% for elacestrant vs 9% for SOC in overall population.
Preclinical data suggest dual ER and PR blockade may enhance tumor control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.